The global cold, cough, and sore throat remedy market is poised for steady growth, with a projected CAGR of 3.40% from 2024 to 2034. The market is estimated to be valued at US$ 42,618.7 million in ...
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
Fitch Solutions has predicted that the naira would slide to as low as N1,993 per dollar in 2028, severely impacting Nigeria’s ...
In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...
He’s openly criticized the FDA and has called for an end to the regulatory oversight of many health products, including ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...
The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused in ... For now, companies may continue to market drug products ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback